Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Yangliang, Fang"'
Publikováno v:
BMC Cardiovascular Disorders, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Lipoprotein (a) [Lp(a)] is an independent risk factor for coronary artery disease (CAD). Recent studies have indicated that statins tend to increase Lp(a) levels by 10–20%. However, the association of statin-mediated increases i
Externí odkaz:
https://doaj.org/article/4f33fe04c0264987af59b28e0d0b90f2
Publikováno v:
BMC Cardiovascular Disorders, Vol 22, Iss 1, Pp 1-2 (2022)
Externí odkaz:
https://doaj.org/article/9250f0ddb457475cac5baf358ba63503
Autor:
Lijun, Zhu, Yangliang, Fang, Beibei, Gao, Xiangbo, Jin, Jiamin, Zheng, Ying, He, Jinyu, Huang
Background Lipoprotein (a) [Lp(a)] is an independent risk factor for coronary artery disease (CAD). Recent studies have indicated that statins tend to increase Lp(a) levels by 10–20%. However, the association of statin-mediated increases in Lp(a) l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eed5064a92bbeb61879d533b3a9d5690
https://doi.org/10.21203/rs.3.rs-2014611/v1
https://doi.org/10.21203/rs.3.rs-2014611/v1
Autor:
Houyong, Zhu, Yu, Ding, Xiaoqun, Xu, Meiya, Li, Yangliang, Fang, Beibei, Gao, Hengyi, Mao, Guoxin, Tong, Liang, Zhou, Jinyu, Huang
Publikováno v:
American journal of translational research. 9(5)
Prostaglandin E1 (PGE1) is used as a pretreatment for ischemia reperfusion injury in many biological systems. However, its value as a pretreatment for coronary microembolization (CME) is unknown. The goal of this study was to determine whether PGE1 w